The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration in recent weeks said it would decline to clarify laws that ban the foreign importation of prescription medicines, despite growing evidence of the overseas schemes. A class of businesses called…
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off a wave of economic and political uncertainty, some companies are still feeling the effects. While some industries have emerged largely unscathed — having weathered twists and turns of several tariff iterations — others, such as retail, automotive,…
The Trump administration on Thursday imposed new tariffs on branded drugs from pharmaceutical companies that have not struck deals with the president to lower their U.S. drug prices – a long-awaited move that will likely only affect a small portion of drugmakers. “We need to make sure that our drug supply is protected, secure and…
Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk rose as much as 4% after England’s drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country. Wegovy is mainly a weight loss treatment…
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly has agreed to pay up to $7.8 billion to acquire Centessa Pharmaceuticals and its experimental drug for excessive daytime sleepiness, the company said Tuesday. Centessa is…
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake | Reuters BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico…
AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of Every Cure A version of this story first appeared in the CNBC Cures newsletter. Click here to sign up. There are over 10,000 rare diseases — 95% of which don’t have a cure. It can cost billions…
Abivax is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell. Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025….
The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. Nurphoto | Nurphoto | Getty Images The first wave of generic versions of Novo Nordisk’s GLP-1 weight-loss drugs launched in India over the weekend, with at least five domestic drugmakers undercutting the original…
